A.P.J. D. V.

The investigator's oncological research encompasses a broad spectrum of solid tumors and hematological malignancies, with emphasis on advanced therapeutic strategies combining immunotherapy and targeted treatments. Significant involvement includes studies on non-small cell lung cancer, particularly in patients with EGFR mutations, exploring extended dosing intervals of osimertinib. The work extends to melanoma, investigating ipilimumab and nivolumab combinations in both neoadjuvant and adjuvant settings, with focus on optimizing treatment duration and response assessment.

• Checkpoint inhibitor therapy in melanoma and lung cancer
• HER2-targeted therapies in esophageal adenocarcinoma
• IDH mutation-targeted treatments in chondrosarcoma and acute myeloid leukemia
• Novel antibody-drug conjugates in HER3-positive solid tumors

Additional areas include muscle invasive bladder cancer with bladder-sparing approaches combining chemoradiation with immunotherapy, head and neck squamous cell carcinoma with modified cisplatin dosing strategies, and metastatic pancreatic ductal adenocarcinoma exploring optimal timing of chemotherapy initiation and novel combination therapies.

This investigator contributes to advancing treatment paradigms in acute myeloid leukemia and myelodysplastic syndrome, with particular focus on molecularly defined patient subgroups. The research investigates IDH1 and IDH2 mutations in newly diagnosed AML patients, evaluating targeted inhibitors such as ivosidenib and enasidenib in combination with intensive chemotherapy and as maintenance therapy. Additional work addresses NPM1-mutated AML in patients ineligible for intensive chemotherapy, exploring novel menin inhibitors combined with azacitidine and venetoclax.

• Targeted therapy for IDH-mutated acute myeloid leukemia
• Treatment strategies for NPM1-mutated AML
• Combination approaches with venetoclax and azacitidine
• Maintenance therapy in molecularly defined leukemia subtypes

The work emphasizes precision medicine approaches based on molecular mutations and optimization of treatment sequences in patients with varying fitness levels for intensive therapy.

The investigator demonstrates expertise in managing complex gastrointestinal malignancies and liver disease. Research in locally advanced rectal cancer explores intensive induction chemotherapy with FOLFOXIRI to improve pathological and clinical complete response rates. Work in ovarian cancer investigates hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery to enhance overall survival. In hepatology, focus areas include prevention of hepatic encephalopathy following transjugular intrahepatic portosystemic shunt placement in patients with alcoholic liver cirrhosis.

• Neoadjuvant and consolidation strategies in rectal cancer
• Hyperthermic intraperitoneal chemotherapy in ovarian cancer
• Prevention of post-TIPS hepatic encephalopathy
• Antibiotic prophylaxis in pancreatoduodenectomy

Additional research addresses surgical site infections following pancreatoduodenectomy in high-risk patients, evaluating pre-emptive antibiotic strategies to reduce infectious complications.

The investigator engages in research addressing rare immunological disorders and specialized conditions requiring targeted therapeutic interventions. Work includes eosinophilic granulomatosis with polyangiitis, evaluating novel long-acting biologic therapies compared to standard treatments. Research in fetal and neonatal alloimmune thrombocytopenia explores alternative approaches to prevent severe maternal-fetal complications. Additional focus encompasses sternocostoclavicular hyperostosis, investigating bisphosphonate therapy for pain management, and tenosynovial giant cell tumour, examining colony-stimulating factor 1 receptor inhibition.

• Biologic therapy for eosinophilic granulomatosis with polyangiitis
• Prevention strategies for fetal and neonatal alloimmune thrombocytopenia
• Pain management in sternocostoclavicular hyperostosis
• Targeted therapy for tenosynovial giant cell tumour

The work extends to type 1 diabetes mellitus, investigating GAD65 antigen-specific immunotherapy to preserve beta cell function in recently diagnosed patients, and asplenia, examining optimal pneumococcal vaccination strategies based on timing relative to splenectomy.